187 related articles for article (PubMed ID: 10492360)
41. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
[TBL] [Abstract][Full Text] [Related]
42. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma.
Reske SN; Grillenberger KG; Glatting G; Port M; Hildebrandt M; Gansauge F; Beger HG
J Nucl Med; 1997 Sep; 38(9):1344-8. PubMed ID: 9293784
[TBL] [Abstract][Full Text] [Related]
43. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
[TBL] [Abstract][Full Text] [Related]
44. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer.
Kittaka H; Takahashi H; Ohigashi H; Gotoh K; Yamada T; Tomita Y; Hasegawa Y; Yano M; Ishikawa O
World J Surg; 2013 Jan; 37(1):169-78. PubMed ID: 22955953
[TBL] [Abstract][Full Text] [Related]
45. Nonfunctioning endocrine pancreatic tumor examined with 18F-FDG PET/CT.
Toshikuni N; Kai K; Fujisawa M
Ann Nucl Med; 2008 Feb; 22(2):133-7. PubMed ID: 18311538
[TBL] [Abstract][Full Text] [Related]
46. Functional imaging of interstitial brachytherapy in pancreatic carcinoma xenografts using spectral CT: how does iodine concentration correlate with standardized uptake value of (18)FDG-PET-CT?
Hu S; Shi X; Chen Y; Huang W; Song Q; Lin X; Liu Y; Chen K; Wang Z
Br J Radiol; 2016; 89(1058):20150573. PubMed ID: 26642307
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET.
Fukunaga T; Okazumi S; Koide Y; Isono K; Imazeki K
J Nucl Med; 1998 Jun; 39(6):1002-7. PubMed ID: 9627333
[TBL] [Abstract][Full Text] [Related]
48. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications.
Nishimura Y; Hosotani R; Shibamoto Y; Kokubo M; Kanamori S; Sasai K; Hiraoka M; Ohshio G; Imamura M; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1997 Aug; 39(1):39-49. PubMed ID: 9300738
[TBL] [Abstract][Full Text] [Related]
49. PET and PET/CT for pancreatic malignancies.
Delbeke D; Martin WH
Surg Oncol Clin N Am; 2010 Apr; 19(2):235-54. PubMed ID: 20159513
[TBL] [Abstract][Full Text] [Related]
50. Is (18)F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis?
Shigekawa M; Yamao K; Sawaki A; Hara K; Takagi T; Bhatia V; Nishio M; Tamaki T; El-Amin H; Sayed Zel-A; Mizuno N
J Hepatobiliary Pancreat Sci; 2010 May; 17(3):269-74. PubMed ID: 19727541
[TBL] [Abstract][Full Text] [Related]
51. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
52. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma.
Zimny M; Fass J; Bares R; Cremerius U; Sabri O; Buechin P; Schumpelick V; Buell U
Scand J Gastroenterol; 2000 Aug; 35(8):883-8. PubMed ID: 10994629
[TBL] [Abstract][Full Text] [Related]
53. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer.
Oku S; Nakagawa K; Momose T; Kumakura Y; Abe A; Watanabe T; Ohtomo K
Ann Nucl Med; 2002 Sep; 16(6):409-16. PubMed ID: 12416580
[TBL] [Abstract][Full Text] [Related]
54. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
55. [18FDG-PET imaging of pancreatic adenocarcinoma].
Daenen F; Hustinx R; Belhocine T; Focan C; Honoré P; Rigo P
Rev Med Liege; 2000 Feb; 55(2):89-94. PubMed ID: 10769575
[TBL] [Abstract][Full Text] [Related]
56. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study.
Higashi T; Tamaki N; Honda T; Torizuka T; Kimura T; Inokuma T; Ohshio G; Hosotani R; Imamura M; Konishi J
J Nucl Med; 1997 Sep; 38(9):1337-44. PubMed ID: 9293783
[TBL] [Abstract][Full Text] [Related]
57. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.
Torizuka T; Zasadny KR; Kison PV; Rommelfanger SG; Kaminski MS; Wahl RL
J Nucl Med; 2000 Jun; 41(6):999-1005. PubMed ID: 10855624
[TBL] [Abstract][Full Text] [Related]
58. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG.
Dimitrakopoulou-Strauss A; Hohenberger P; Haberkorn U; Mäcke HR; Eisenhut M; Strauss LG
J Nucl Med; 2007 Aug; 48(8):1245-50. PubMed ID: 17631559
[TBL] [Abstract][Full Text] [Related]
59. 18F alpha-methyl tyrosine PET studies in patients with brain tumors.
Inoue T; Shibasaki T; Oriuchi N; Aoyagi K; Tomiyoshi K; Amano S; Mikuni M; Ida I; Aoki J; Endo K
J Nucl Med; 1999 Mar; 40(3):399-405. PubMed ID: 10086702
[TBL] [Abstract][Full Text] [Related]
60. The role of intraoperative radiotherapy (IORT) in the management of patients with pancreatic and periampullary cancer: A single center experience.
Zaki Azzam A; Alqarni A; Mahmoud Amin T
J Egypt Natl Canc Inst; 2018 Jun; 30(2):77-79. PubMed ID: 29680448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
